Correlation between MRI characteristics of medulloblastoma with histopathological subtypes and 2-year survival

Intan Zariza Hussain, Faizah Mohd Zaki, Shahizon Azura Mukari, Suria Hayati Md Pauzi, C-Khai Loh, Hamidah Alias

Departments of Radiology, Pathology and Pediatrics, Universiti Kebangsaan Malaysia Medical Center, Jalan Yaacob Latif, 56000 Cheras, Kuala Lumpur, Malaysia

Correspondence: Dr. Faizah Mohd Zaki, Department of Radiology, Universiti Kebangsaan Malaysia Medical Center, Jalan Yaacob Latif, 56000 Cheras, Kuala Lumpur, Malaysia. E-mail: faizahbangi@yahoo.co.uk

Abstract

Objectives: The objective of this study is to describe the imaging features of medulloblastoma (MB) and correlate the MR characteristics with the different histological subtype of MB with 2-year survival. Materials and Methods: This is a retrospective descriptive study. A total of 29 patients diagnosed with MB from January 2005 to December 2015 were included in this study. The MRI brain and spine studies of these patients were retrieved and reviewed by a pediatric radiologist and a neuroradiologist independently, both blinded from the histological type of the MB. The HPE slides were also retrieved and reviewed by a pathologist. Results: 80% of desmoplastic MB showed the presence of intracranial leptomeningeal seeding and 57.1% of anaplastic MB showed the presence of necrosis. The presence of intracranial leptomeningeal seeding (P = 0.002) and necrosis (P = 0.019) was predictive of the histological subtypes. There is a significant correlation between the enhancement pattern and the 2-year outcome (P = 0.03) with 6 out of 8 patients whose tumors showed minimal enhancement having disease progression within 2 years. A significant correlation was also seen between the presence of necrosis with a poorer outcome (P = 0.03) and between the HPE subtype and 2-year outcome (P = 0.03) with anaplastic MB having the poorest prognosis. Conclusion: MR imaging features of intracranial leptomeningeal seeding and the presence of necrosis correlated with 2-year outcome of the disease.

Key words: Medulloblastoma; MRI; survival

Introduction

Medulloblastoma (MB) is a malignant neuroepithelial tumor and is considered the most common malignant tumor of the posterior fossa in children (30%–40%). They are thought to arise from primitive cells of the external granular layer of the cerebellum, which persists until the beginning of the second year of life.[1]

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com
The World Health Organization (WHO), in the 2016 edition of *WHO Classification of Tumors of the Central Nervous System*, defines MB as a malignant, invasive embryonal neoplasm of the cerebellum with a tendency for CSF dissemination. MB are universally classified as grade IV because of their aggressive nature, with malignant cytologic features, rapid disease evolution, and a fatal outcome if not treated with multimodal therapies. These tumors were classified based on their histological subtypes that have been long-established: desmoplastic, MB with extensive nodularity, and large cell (LC) or anaplastic MB. Updated classification has been made based on genetic (molecular) subgroups of MB, namely, WNT-activated, SHH-activated, group 3 and group 4 MB.[3]

MR imaging is performed in all patients with brain tumor and remains the primary method for diagnosis, surgical guidance, and surveillance of these tumors. MRI can be used as primary imaging technique in such patients prior to surgery, during the follow-up, and in postoperative phase.[3]

Prior studies have shown that MBs present with heterogeneous imaging features, including location and enhancement patterns. These phenotypic radiologic features may reflect underlying differences in tumor biology.[3]

Histopathology is an important prognostic factor, particularly in young children. The impact of histopathology was studied in a cohort of 260 children less than 5 years of age who were treated on national protocols in Europe and the United States. Even after accounting for stage (the presence of metastases, residual disease), patients with desmoplastic/nodular or desmoplastic with extensive nodularity had a significantly better event-free and overall survival compared with the classic form of MB on multivariate analysis. In contrast, those with large cell or anaplastic variants had a significantly poorer prognosis.[4]

In our institution, MBs are not characterized into their molecular subgroups, but they are classified according to their histological characteristics (i.e., Classic, MB with extensive nodularity, Desmoplastic, and Anaplastic/Large cell). In this study, we hypothesized that distinct MR imaging features can predict the histopathological subtype of pediatric MB and whether these MRI features can predict and prognosticate the disease.[3]

**Materials and Methods**

**Ethical consideration**

Ethical approval was obtained from the institution Research and Ethics Committee in January 2017 (project code: FF-2017-016). This is a retrospective descriptive study and informed consent was waived.

**Subject and procedures**

The study was conducted in the Radiology Department in a tertiary university hospital. The retrospective analysis was based on patient data collected from the Coding Unit, Health Information Department using a word search of “medulloblastoma.” MRI brain was performed using Siemens 1.5T with multiple sequences included: T1, T2, gradient echo sequence, FLAIR, and postcontrast sequences. Meanwhile, MRI spine included T1 T2, STIR, and postcontrast sequences, which was performed at the same setting or few days later depending on the clinical situation at that time.

**Data collection and statistical analysis**

The MRI brain and spine studies of these patients were retrieved and reviewed by a pediatric radiologist and a neuroradiologist independently, both blinded from the HPE. The HPE slides were also retrieved and reviewed by a pathologist.

The MR imaging features assessed included tumor location, enhancement pattern, cysts/cavities, hemorrhage/mineralization, tumor margin, necrosis as suggested by ring-enhancement on post-gadolinium images, intracranial or leptomeningeal seeding, and intraspinal drop metastases. Necrosis often has irregular and thicker margin with some heterogeneity within the lesion on T2 WI. Meanwhile, cysts have smoother margin with homogenous high T2 signal within it.

“Tumor location” was defined as midline vermin/fourth ventricle, cerebellar hemisphere, or cerebellar peduncle/cerebellopontine angle cistern (CP/CPA).

“Tumor margin” was characterized as ill-defined if >50% of the margin could not be distinguished from the surrounding cerebellar parenchyma on the basis of all imaging sequences. “Enhancement pattern” was defined as minimal/none if <10% was estimated to enhance, solid if >90% of the tumor volume was estimated to enhance, and heterogeneous if varying degrees of enhancement were seen in 10%–90% of the tumor volume on the basis of radiologists’ visual assessments. Low signal on 2D gradient recalled-echo was used to detect hemorrhage/mineralization.

A pathologist re-reviewed the histopathology slides and classified the histopathological examination (HPE) into four main HPE subtypes of classic MB, desmoplastic MB, MB with extensive nodularity, or large cell (LC) or anaplastic MB. The statistical analysis was performed using SPSS software package IBM version 25.

**Results**

A total of 29 patients with MRI brain imaging and histopathological results were included in the study.
Nineteen were male and 10 were female patients. The youngest patient was 3 months old and the oldest was 16 years old, with a mean age of 8.97 years. Out of the 29 subjects, twenty-two were Malay (75.9%), four Chinese (13.8%), two Indian (6.9%), and 1 (3.4%) was of Somali (3.4%) ethnicities.

All these subjects underwent surgery with tissue samples sent for histopathological diagnosis, subsequently had chemotherapy and/or radiotherapy. Seventeen patients (58.6%) were diagnosed with Classic type MB, seven patients (24.1%) diagnosed with Anaplastic/Large Cell MB, and five patients (17.2%) diagnosed with Desmoplastic MB. On 2-year follow-up, sixteen of the patients were disease/progression free (55.2%) and twelve had disease progression (41.4%) and one died (3.4%).

MR imaging correlation of histopathological subtypes
80% of desmoplastic MBs showed the presence of intracranial leptomeningeal seeding [Figure 2] and 57.1% of anaplastic MBs showed the presence of necrosis. The presence of intracranial leptomeningeal seeding (P = 0.002) and necrosis (P = 0.019) was predictive of the histological subtypes. A summary of the findings can be found in Table 1.

We also observed that the tumor does extend through the Luschka’s foramina in 34.5% of case (n = 10) while 13.7% extend through both Luschka’s and Magendie’s foramen [Figure 2].

MR imaging correlation of 2-year outcome
There is a significant correlation between the enhancement pattern and the 2-year outcome (P = 0.04) with 6 out of 8 patients (75%) whose tumors showed minimal enhancement having disease progression within 2 years [Figure 3]. A summary of the findings can be found in Table 2.

There is also a significant correlation between the presence of necrosis with a poorer outcome (P = 0.03). Five out of six patients whose tumors had necrotic component had disease progression within the 2-year follow-up period.

We found no significant correlation between the outcome with location (P = 0.653), margin of tumor (P = 0.198), cysts/cavities (P = 0.113), hemorrhage/mineralization (P = 0.321), intracranial leptomeningeal seeding (P = 0.436), and intraspinal drop metastases (P = 0.730).

HPE correlation with 2-year outcome
There is a significant correlation between the HPE subtype and 2-year outcome with anaplastic MB having the poorest prognosis (P = 0.03); six out of seven patients (85.7%) had subsequent disease progression, as shown in Table 3.

Discussion
MBs occur in childhood and adolescence with a remarkable decrease in incidence at the second and third decades of life. In this study, patients age ranges between 3 months old to 16 years old with a mean age of 8.97 years. The incidence is higher in males with a male: female ratio of 1.5:2:1. In this study, a ratio of 1.9:11.9:1 was observed which is concordant with the previous studies.
As noted by Robinson, while no single tumor feature should be used alone to determine tumor subtype or tailor treatment, MR imaging can offer additional opportunities. Several studies have investigated the use of magnetic resonance imaging (MRI) as a means to differentiate histological subtypes. The preferential site of this tumor is midline in the posterior fossa in 26 patients (89.7%). A more lateral involvement of the cerebellar peduncle/CP angle was found in 1 subject (3.4%) from the anaplastic MB group and 2 subjects (6.9%) with tumors centered in the cerebellar vermis. Tumor extension through the fourth ventricle drainage foramina has been associated with ependymoma. However, MBs generally grow into and fill the fourth ventricle. 

**Table 1: Summary of histologic subtype of medulloblastoma and the MRI features**

| Tumor Location       | Classic (n=17) | Anaplastic/Large Cell (n=7) | Desmoplastic (n=5) | Total (n=29) | P     |
|----------------------|---------------|-----------------------------|-------------------|--------------|-------|
| Midline              | 16 (94.2%)    | 6 (85.7%)                   | 4 (80%)           | 26 (89.7%)   | P=0.29|
| CP/CPA               | 0             | 1 (14.3%)                   | 0                 | 1 (3.4%)     |       |
| Cerebellar hemisphere| 1 (5.8%)      | 0                           | 1 (20%)           | 2 (6.9%)     |       |
| Margin               |               |                             |                   |              |       |
| Well-defined         | 10 (58.8%)    | 1 (14.3%)                   | 4 (80%)           | 15 (51.7%)   | P=0.053|
| Ill-defined          | 7 (41.2%)     | 6 (85.7%)                   | 1 (20%)           | 14 (48.3%)   |       |
| Enhancements         |               |                             |                   |              |       |
| Minimal              | 3 (17.6%)     | 4 (57.1%)                   | 1 (20%)           | 8 (27.6%)    | P=0.313|
| Homogenous           | 4 (23.5%)     | 1 (14.3%)                   | 2 (40%)           | 7 (24.1%)    |       |
| Heterogenous         | 10 (58.8%)    | 2 (28.6%)                   | 2 (40%)           | 14 (48.3%)   |       |
| Characteristics      |               |                             |                   |              |       |
| Cyst/Cavities        | 13 (76.5%)    | 4 (57.1%)                   | 3 (60%)           | 20 (69%)     | P=0.579|
| Hemorrhage/Mineralization | 12 (70.6%) | 6 (85.7%)                   | 4 (80%)           | 22 (75.9%)   | P=0.713|
| Necrosis             | 1 (5.8%)      | 4 (57.1%)                   | 1 (20%)           | 6 (20.7%)    | P=0.019*|
| Intracranial leptomeningeal seeding | 1 (5.8%) | 4 (57.1%)                   | 4 (80%)           | 9 (31.3%)    | P=0.002*|
| Intraspinal drop metastases | 3 (17.6%) | 3 (42.9%)                   | 2 (40%)           | 8 (27.6%)    | P=0.360|

*P<0.05

| Table 2: Summary of 2-year clinical outcome and the MRI features of medulloblastoma |
|--------------------------------------|-----------------|-----------------|-----------|
| Location                             | Progression Free (n=16) | Disease progression (n=13) | P     |
|                                     |                  |                  |           |
| Midline                             | 14 (87.4%)       | 12 (92.3%)       | P=0.653 |
| CP/CPA                              | 1 (6.3%)         | 0                |           |
| Cerebellar Hemisphere                | 1 (6.3%)         | 1 (7.7%)         |           |
| Margin                              |                  |                  |           |
| Well-defined                        | 10 (62.5%)       | 5 (38.5%)        | P=0.198 |
| Ill-defined                          | 6 (37.5%)        | 8 (61.5%)        |           |
| Enhancement                          |                  |                  |           |
| Minimal                             | 2 (12.5%)        | 6 (46.2%)        | P=0.039*|
| Homogenous                          | 3 (18.8%)        | 4 (30.8%)        |           |
| Heterogenous                        | 11 (68.7%)       | 3 (23%)          |           |
| Characteristics                     |                  |                  |           |
| Cyst/Cavities                       | 13 (81.3%)       | 7 (53.8%)        | P=0.113 |
| Hemorrhage/Mineralization           | 11 (68.8%)       | 11 (84.6%)       | P=0.321 |
| Necrosis                            | 1 (6.3%)         | 5 (38.5%)        | P=0.033*|
| Intracranial leptomeningeal seeding | 4 (25%)          | 5 (38.5%)        | P=0.436 |
| Intraspinal drop metastases         | 4 (25%)          | 4 (30.8%)        | P=0.730 |

*P<0.05

| Table 3: 2-year outcome of each histologic subtype of MB |
|--------------------------------------------------------|
| Outcome | Total |      |      |
|         | Disease Free | Progression/Death |      |
| HPE     |       |      |      |
| Classic | 11    | 6    | 17   |
| Anaplastic | 1  | 6    | 7    |
| Desmoplastic | 4  | 1    | 5    |
| Total   | 16    | 13   | 29   |

P<0.05 (0.03)
ventricle and may extend through the Magendie’s and Luschka’s foramina.[6,8] This was also observed in our study in which 34.5% tumors extend through the Luschka’s foramina [Figure 2] and 13.7% extend through both Luschka’s and Magendie’s foramen. These findings emphasize the necessity of including MB in the differential diagnosis of tumors affecting these foramina.

According to the previous literatures, MBs present heterogenous signal associated with the presence of cysts, necrosis, small blood vessels, and/or calcifications.[10‑12] We postulated this is because poor enhancement related to less neovascularization within the tumor, causing less concentration of chemotherapy that can reach the tumour. In view of the less effective chemotherapy target to the tumour, thus it causes poorer prognosis. Pattern of our results was very much concordance with the above-mentioned findings, where minimal enhancement of the tumor was observed in 27.6% cases, and homogenous enhancement in 24.1% cases, while the remaining 48.3% cases, there was heterogenous enhancement [Figure 3]. We have also observed that almost half of the MB cases that presented with minimal enhancement were associated with poorer outcome (46.2%) (P = 0.039).

In the present study, the presence of intracranial leptomeningeal seeding was found in 57.1% of cases in the anaplastic histological type, 80% of cases in the desmoplastic type, and 5% of cases in the classic type [Figure 3]. This is discordant with the previous literatures that concluded the presence of leptomeningeal spread was positively correlated with the anaplastic or large cell subtype and inversely correlated with the classic and desmoplastic subtype.[2,7‑9] This may be due to the small sample size and unequal distributions between the number of each histologic types in this study.

On the other hand, we found that the presence of intraspinal leptomeningeal seeding does not correlate with poorer outcome (P = 0.730), which may be attributed to similar reason.

Necrosis was observed in 20.1% of cases and it correlates with the anaplastic type, which also correlates with poorer outcome in which 83.3% of cases progressed. This is consistent with the previous literatures, whereby anaplastic/large cell MB has been associated with poorer outcome.[10‑12] We did not find a correlation between other MRI features with the histologic subtype of MB.

This study was limited by its retrospective nature. We were unable to retrieve some imaging studies specifically those done in other centers. In addition, some heterogeneity in imaging protocols reduced the sample size for some components of our analysis, excluding some of the patients who did not have imaging of the spine done in our center.

A larger sample size is needed for better evaluation of the correlation between MR features and histopathologic subtype of MB, as well as the 2-year outcome in order to obtain more concrete and statistically significant association.

Conclusion

MR imaging features of intracranial leptomeningeal seeding and the presence of necrosis were correlated with specific histologic subtype of MB. The enhancement pattern as well as necrosis correlated with the poorer 2-year outcome of the disease. This study supports an important step in using MR imaging as a surrogate to predict histologic subtype of MB. A study in larger group of sample size is needed to evaluate the risk of assessments of MRI characters in the future.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References

1. Fruehwald-Pallamar J, Puchner SB, Rossi A, Garre ML. Magnetic resonance imaging spectrum of medulloblastoma. Neuroradiology 2011;53:387‑96.
2. Louis DN, Perry A, Reifenberger G, Deimling AV, Cavenee WK, et al. The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016;131:803‑20.
3. Yeom KW, Mobley BC, Lober RM, Andre JB, Partap S, Barnes PD, et al. Distinctive MRI features of pediatric medulloblastoma subtypes. Am J Roentgenol 2013;200:895‑903.
4. Perreault S, Ramaswamy V, Achrol AS, Chao K, Liu TT, Shih D, et al. MRI surrogates for molecular subgroups of medulloblastoma. Am J Neuroradiol 2014;35:1263‑9.
5. Meyers SP, Kemp SS, Tarr RW. MR Imaging features of medulloblastoma. Am J Roentgenol 1992;158:859‑65.
6. Northcott PA, Korshunov A, Witt H, Hielser T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29:1408‑14.
7. Robinson G, Impact of tumor location on medulloblastoma subtyping and treatment. Pediatr Blood Cancer 2013;60:1393‑4.
8. Vieira M, Melo D, Amaral G, Rodrigues MO, Concepción M, Otaduy G, T. et al. Medulloblastoma: Correlation among findings of conventional magnetic resonance imaging, diffusion-weighted imaging and proton magnetic resonance spectroscopy. Radiol Bras 2016;49:472‑81.
9. Ahmad T, Gohar M. MRI evaluation of medulloblastoma with histopahtological correlation. Biomedica 2014;30:1-5.
10. Huang PI, Lin SC, Lee YY, Ho DMT, Guo WY, Chang KP, et al. Large cell/anaplastic medulloblastoma is associated with poor prognosis—A retrospective analysis at a single institute. Childs Nerv Syst 2017;33:1285-94.
11. Raleigh DR, Varenika V, Tihan T, Daphne A. Radiographic and molecular classification of medulloblastoma. JSM Clin Oncol Res 2014;2:1-10.
12. Rutkowski S, von Hoff K, Emser A, Zwiener I, Pietsch T, Figarella-Branger D, et al. Survival and prognostic factors of early childhood medulloblastoma: An international meta-analysis. J Clin Oncol 2010;28:4961-8.